ACE Inhibitors in Cardiovascular Disease — Unbeatable?  

Oleh:

McMurray, John J.V.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 15 (Apr. 2008), page 1615.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET, NCT00153101 [ClinicalTrials.gov] ), reported by Yusuf et al.1 in this issue of the Journal, has important lessons for clinical practice and also illustrates the complexities of designing, conducting, analyzing, and interpreting trials comparing new treatments that act in a manner similar to that of established therapies. As the fourth and largest comparative trial, the ONTARGET study confirms, beyond doubt, that angiotensin-receptor blockers (ARBs) are not better than angiotensin-converting–enzyme (ACE) inhibitors at reducing fatal and nonfatal cardiovascular events. Of course, physicians and patients might still choose to use an . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali